Albert W. Gianchetti
Vorstandsvorsitzender bei Xylocor Therapeutics, Inc.
Aktive Positionen von Albert W. Gianchetti
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Direktor/Vorstandsmitglied | - | - |
| Vorstandsvorsitzender | - | - | |
| Präsident | - | - |
Karriereverlauf von Albert W. Gianchetti
Ehemalige bekannte Positionen von Albert W. Gianchetti
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| VANDA PHARMACEUTICALS INC. | Corporate Officer/Principal | 25.10.2007 | 01.12.2008 |
| GSK PLC | Corporate Officer/Principal | - | - |
Ausbildung von Albert W. Gianchetti
| University of Delaware | Undergraduate Degree |
| Drexel University | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 5 |
| Vereinigtes Königreich | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VANDA PHARMACEUTICALS INC. | Health Technology |
| GSK PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
- Börse
- Insiders
- Albert W. Gianchetti
- Erfahrung
